Pier Luigi Filosso1, Francesco Guerrera1, Andrea Evangelista2, Claudia Galassi2, Stefan Welter3, Erino Angelo Rendina4, William Travis5, Eric Lim6, Inderpal Sarkaria7, Pascal Alexandre Thomas8. 1. Department of Thoracic Surgery, University of Torino, Torino, Italy. 2. Unit of Cancer Epidemiology and CPO Piedmont, Città della Salute e della Scienza University Hospital, Torino, Italy. 3. Rurhlandklinik, Westgerman Lung Center, University Hospital, University of Duisburg-Essen, Essen, Germany. 4. Sapienza University of Rome, Fondazione Eleonora Lorillard Spencer Cenci, S. Andrea Hospital, Rome, Italy. 5. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 6. Royal Brompton Hospital, Unit of Thoracic Surgery, London, UK. 7. UPMC/University of Pittsburgh, Schools of the Health Sciences, Pittsburgh, PA, USA. 8. Department of Thoracic Surgery, Lung Transplantation and Diseases of the Esophagus, Aix-Marseille University and Hospitals System of Marseille (AP-HM), Marseille, France.
Abstract
OBJECTIVES: Large-cell neuroendocrine carcinoma (LCNC) is a rare tumour characterized by aggressive biological behaviour and poor prognosis. Due to its rarity and the lack of randomized clinical trials, the best treatment is still under debate. Some recent reports indicate that adjuvant chemotherapy (CT) may have a beneficial effect on survival. Our goal was to evaluate this finding using a large series of patients with neuroendocrine tumours obtained from the European Society of Thoracic Surgeons database. METHODS: Data for 400 patients with LCNC operated on in 14 thoracic surgery institutions worldwide between 1992 and 2014 were collected retrospectively. Overall survival was the primary endpoint; we used a multivariable Cox regression model to evaluate which clinical variables may influence patient outcomes; we also focused on the possible prognostic role of adjuvant CT. A propensity score (PS) analysis using the inverse probability of treatment weighting was also carried out. RESULTS: The 3- and 5-year survival rates were 54.1% and 45%, respectively. With the multivariable model, we found that increasing age, Eastern Cooperative Oncology Group Performance Status ≥2 and advanced TNM stage were indicators of poor prognosis. Weak evidence of a higher overall survival in patients receiving adjuvant CT (adjusted hazard ratio 0.73; 95% confidence interval: 0.56-0.96, P = 0.022) was observed. CONCLUSIONS: A trend towards benefit from adjuvant CT has been observed in patients with LCNC. Although surgical procedures remain the mainstay of curative options, combination with other treatments (e.g. neoadjuvant CT/radiotherapy) should be evaluated by future studies.
OBJECTIVES: Large-cell neuroendocrine carcinoma (LCNC) is a rare tumour characterized by aggressive biological behaviour and poor prognosis. Due to its rarity and the lack of randomized clinical trials, the best treatment is still under debate. Some recent reports indicate that adjuvant chemotherapy (CT) may have a beneficial effect on survival. Our goal was to evaluate this finding using a large series of patients with neuroendocrine tumours obtained from the European Society of Thoracic Surgeons database. METHODS: Data for 400 patients with LCNC operated on in 14 thoracic surgery institutions worldwide between 1992 and 2014 were collected retrospectively. Overall survival was the primary endpoint; we used a multivariable Cox regression model to evaluate which clinical variables may influence patient outcomes; we also focused on the possible prognostic role of adjuvant CT. A propensity score (PS) analysis using the inverse probability of treatment weighting was also carried out. RESULTS: The 3- and 5-year survival rates were 54.1% and 45%, respectively. With the multivariable model, we found that increasing age, Eastern Cooperative Oncology Group Performance Status ≥2 and advanced TNM stage were indicators of poor prognosis. Weak evidence of a higher overall survival in patients receiving adjuvant CT (adjusted hazard ratio 0.73; 95% confidence interval: 0.56-0.96, P = 0.022) was observed. CONCLUSIONS: A trend towards benefit from adjuvant CT has been observed in patients with LCNC. Although surgical procedures remain the mainstay of curative options, combination with other treatments (e.g. neoadjuvant CT/radiotherapy) should be evaluated by future studies.
Authors: Maria Cattoni; Eric Vallières; Lisa M Brown; Amir A Sarkeshik; Stefano Margaritora; Alessandra Siciliani; Pier Luigi Filosso; Francesco Guerrera; Andrea Imperatori; Nicola Rotolo; Farhood Farjah; Grace Wandell; Kimberly Costas; Catherine Mann; Michal Hubka; Stephen Kaplan; Alexander S Farivar; Ralph W Aye; Brian E Louie Journal: World J Surg Date: 2019-07 Impact factor: 3.352
Authors: Vignesh Raman; Oliver K Jawitz; Chi-Fu J Yang; Betty C Tong; Thomas A D'Amico; Mark F Berry; David H Harpole Journal: Ann Thorac Surg Date: 2019-04-18 Impact factor: 4.330
Authors: Christian Roesel; Stefan Welter; Karl-Otto Kambartel; Gerhard Weinreich; Thomas Krbek; Monika Serke; Mohammed Ibrahim; Yazan Alnajdawi; Till Plönes; Clemens Aigner Journal: J Thorac Dis Date: 2020-03 Impact factor: 2.895
Authors: Michael S May; Connor J Kinslow; Christopher Adams; Anjali Saqi; Catherine A Shu; Kunal R Chaudhary; Tony J C Wang; Simon K Cheng Journal: Transl Lung Cancer Res Date: 2021-01